ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CLPT / options
MOBI (50) EMBC (68) OFIX (42) SI (44) ⌘ Pro Terminal →

ClearPoint Neuro Inc. (CLPT) Options Positioning, Max Pain & Unusual Sweeps

$9.95 -6.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.81

ClearPoint Neuro Inc. (CLPT) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $342.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLPT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, ClearPoint Neuro Inc. (NASDAQ: CLPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $9.95 (-6.75% 1D, market cap $342.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLPT ranks #994 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLPT compare to MOBI and EMBC in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), CLPT carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 61.4%, and ROIC of -35.0%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M) and EMBC (Embecta Corp.) posts a C+ grade (68/100 RQD, P/E 3.9x, ROIC 35.5%, cap $354.1M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLPT?
▼

Per CLPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285550), ClearPoint Neuro Inc. generated $37.0M in revenue (+17.8% YoY), -$25.5M in net income, and -$24.4M in free cash flow against $97.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.81 (-1.40%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (19/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510019
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (5)SEC (6)Macro (3)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-17.6% Base Target
$21 Bull$8 Base$6 Bear
📬 FREE CLPT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLPT)Realized 20D OHLCV Swing Band: ±11.2%
Deterministic 5-Pillar Attribution (19/100 Composite)
🔍 WHY CLPT SCORES 19/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (32% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+5/20 pts (26% of score)

20D Institutional Volume Accumulation (±11.2% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
15
Grade E$9.81-3.7% Next Q
Q2 (-2Q)
16
Grade E$9.45+2.5% Next Q
Q3 (-1Q)
18
Grade E$9.69+2.7% Next Q
Current
19
Grade E$9.95-12% Hist 90D α
Trajectory: E (15) → E (19)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLPT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLPT currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.32) and Max Pain ($10.45) forces dealer call-delta covering toward $20.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 19%NO 81%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±11.2%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CLPT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CLPT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLPT)

  • ✓Walkthrough of CLPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CLPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.00%▼ DESCENDING CHANNEL
2026-11-03O $10.69H $10.69L $9.95C $9.95VOL 916.6K
RES: $14.89SUP: $8.80SMA50: $12.32SMA200: $12.92
$20.38$17.27$14.16$11.05$7.95RES $14.89SUP $8.80$9.952026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLPT Butterfly Map → + Track CLPT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +17.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CLPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLPT)

Health Care Rank #994 of 1016 ⚔️ MOBI vs CLPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLPT vs. MOBI, EMBC, OFIX, SI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ClearPoint Neuro Inc. (CLPT) ranks #994 by composite RQD confidence (19/100, grade E) and #500 by equity capitalization ($342.0M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with CLPT at 19/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLPT ACTIVE
ClearPoint Neuro Inc.
E 19/100 — 61.4% -35.0% -6.75% $342.0M Benchmark Subject
MOBI
Mobia Medical Inc.
D 50/100 — — — -4.82% $352.2M /mobi-vs-clpt →
EMBC
Embecta Corp.
C+ 68/100 3.9x 62.6% 35.5% -0.96% $354.1M /embc-vs-clpt →
OFIX
Orthofix Medical Inc.
D- 42/100 — 68.8% -12.2% -3.53% $369.4M /ofix-vs-clpt →
SI
Shoulder Innovations Inc.
D 44/100 — 76.5% -16.1% +0.99% $398.3M /si-vs-clpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001285550

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ClearPoint Neuro Inc. (CLPT) reported GAAP revenue of $37.0M (+17.8% vs. FY2024 revenue of $31.4M , and +54.3% cumulative change since FY2023) , GAAP net income of -$25.5M, operating cash flow of -$23.9M, and free cash flow of -$24.4M (-164.7% YoY). On the balance sheet, CLPT closed FY2025 with $97.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $37.0M -$25.5M -$23.9M -$24.4M $97.7M —
FY2024 (FY) 2024-12-31 $31.4M -$18.9M -$8.9M -$9.2M $39.2M —
FY2023 (FY) 2023-12-31 $24.0M -$22.1M -$13.7M -$13.7M — —

3. CLPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ClearPoint Neuro Inc. (NASDAQ: CLPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $9.95 (-6.75% 1D, market cap $342.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 3/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLPT ranks #994 in composite RQD confidence.

How does CLPT compare to MOBI and EMBC in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CLPT carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 61.4%, and ROIC of -35.0%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M) and EMBC (Embecta Corp.) posts a C+ grade (68/100 RQD, P/E 3.9x, ROIC 35.5%, cap $354.1M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLPT?

Per CLPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001285550), ClearPoint Neuro Inc. generated $37.0M in revenue (+17.8% YoY), -$25.5M in net income, and -$24.4M in free cash flow against $97.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLPT trading relative to its 50-day, 200-day, and 52-week technical levels?

CLPT last traded at $9.95 (-6.75% on volume of 708,173 shares), positioning the stock -19.24% below its 50-day simple moving average ($12.32) and -22.99% below its 200-day simple moving average ($12.92). Across its 52-week range of $8.27 to $19.68, CLPT sits at the 14.7% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($8.84 to $11.06).

Direct Sub-Reports: CLPT RQD Cockpit CLPT 12M Forecast CLPT Earnings & Move CLPT Dividends & DRIP CLPT Insiders & 13F CLPT Whale Options CLPT Profit Sankey CLPT News & Why
ROARABLE RATING BRIEF • RQD 19/100 (E) ✓ SEC XBRL & RQD VERIFIED

CLPT — ClearPoint Neuro Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

ClearPoint Neuro Inc. (CLPT) earns a live Roarable RQD composite score of 19/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $9.95 (-6.75% 1D, market capitalization $342.0M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 61.4%, operating margin of -60.0%, and free cash flow yield of -7.13%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (3/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

ClearPoint Neuro Inc. Is a NASDAQ-listed company classified in the Health Care sector and the Medical/Dental Instruments industry. The profile identifies the company's market capitalization as $0.3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ClearPoint Neuro Inc. (CLPT) reported $37.0M in annual revenue (up from $31.4M in FY2024, +17.8% YoY) and -$25.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.0M revenue, -$22.1M net income) through FY2025, CLPT scaled operating cash flow to -$23.9M and free cash flow to -$24.4M, backed by $97.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 19/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.13% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $8.27 – $19.68 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), CLPT carries a macro regime beta of 1.00 and gross margin of 61.4%.

  • Key Question #1: Can CLPT sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $37.0M and free cash flow of -$24.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CLPT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CLPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ClearPoint Neuro Inc. (CLPT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLPT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLPT Bull vs. Bear Conversation Board — What's Your Call at $9.95?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLPT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CLPT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $13.02 (+22.0%)
📌 Pinned Debate

Revenue grew from $24.0M in FY 2023 to $37.0M in FY 2025 with a reported gross margin of 61.4%.

Picked up a starter position in CLPT in my $100K Virtual Cash book at $10.67. Revenue grew from $24.0M in FY 2023 to $37.0M in FY 2025 with a reported gross margin of 61.4%.. Trading inside a $8.27–$19.68 52-week range with -7.13% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

CapAlloc_Nerd 🐂 BULL

@QuantViper Agree on the RQD 19/100 quality, though with 1.0 beta I'm scaling in with half-size at $10.67 and keeping dry powder in case we test $9.92.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $8.11 (-24.0%)
Spot @ $10.67

Operating margin of -60% and FY 2025 FCF of -$24.4M against an Altman Z-Score of 0.2 signal distress risk.

Fading this rally in CLPT at $10.67. Operating margin of -60% and FY 2025 FCF of -$24.4M against an Altman Z-Score of 0.2 signal distress risk.. With a beta of 1.0 and the stock sitting at $10.67 (52-wk range $8.27–$19.68), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%